Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Cancer Res ; 38(7): 2180-4, 1978 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-207425

RESUMO

The antitumor activity of 2,3-dihydroxybutyraldehyde on Ehrlich carcinoma, Sarcoma 180, and Yoshida AH 130 hepatoma, as well as the aldehyde dehydrogenase activity in these tumors, was studied. 2,3-Dihydroxybutyraldehyde at nontoxic doses (500 mg/kg body weight i.p. daily for 7 days) slowed down the growth of solid and ascites tumors in mice. The treatment completely prevented the development of Yoshida ascites hepatoma in several rats. 2,3-Dihydroxybutyraldehyde, although it did not influence the growth of Ehrlich carcinoma transplanted in the brain of mice, significantly decreased in the lungs of these animals the number of viable tumour cells that derived from the primary tumor. All the tested tumors, which were sensitive to the action of 2,3-dihydroxybutyraldehyde, were virtually devoid of aldehyde dehydrogenase activity. These results suggest a possible relationship between the lack of this enzyme activity and the antitumor activity of aliphatic aldehydes.


Assuntos
Aldeídos/farmacologia , Antineoplásicos , Butileno Glicóis/farmacologia , Carcinoma de Ehrlich/tratamento farmacológico , Carcinoma Hepatocelular/tratamento farmacológico , Neoplasias Hepáticas/tratamento farmacológico , Sarcoma 180/tratamento farmacológico , Aldeído Oxirredutases/metabolismo , Aldeídos/toxicidade , Animais , Butileno Glicóis/toxicidade , Carcinoma de Ehrlich/enzimologia , Carcinoma Hepatocelular/enzimologia , Feminino , Neoplasias Hepáticas/enzimologia , Camundongos , Neoplasias Experimentais/tratamento farmacológico , Sarcoma 180/enzimologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...